Theravance Biopharma TBPH Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $107.46M+66.9% | $64.38M+12.1% | $57.42M+11.8% | $51.35M-7.2% | ||
| $37.41M-0.6% | $37.64M-7.3% | $40.62M-35.9% | $63.39M-67.3% | ||
| $73.65M+6.5% | $69.17M-1.3% | $70.1M+4.5% | $67.07M-32.5% | ||
| $111.07M-0.2% | $111.33M-1.9% | $113.46M-20.8% | $143.3M-54.2% | ||
| -$3.6M+92.3% | -$46.95M+16.2% | -$56.04M+39.1% | -$91.96M+64.3% | ||
| -3.4%+69.6pp | -72.9%+24.7pp | -97.6%+81.5pp | -179.1%+287pp | ||
| $2.46M-3.3% | $2.55M+8.3% | $2.35M-63.1% | $6.37M-77.1% | ||
| $10.17M+108% | $4.88M-46.5% | $9.12M+6.7% | $8.55M+671% | ||
| $129.25M+390% | -$44.61M+9.4% | -$49.27M+46.9% | -$92.82M+62.3% | ||
| $23.35M+97.8% | $11.8M+99.3% | $5.92M— | —— | ||
| $105.9M+288% | -$56.42M-2.2% | -$55.19M-106% | $872.13M+537% | ||
| 98.5%+186pp | -87.6%+8.5pp | -96.1%-1,795pp | 1,698.5%+2,059pp | ||
| $2.03+277% | -$1.15-18.6% | -$0.97-108% | $11.54+491% | ||
| -$1.98M+95.6% | -$45.24M+16.3% | -$54.03M+38.8% | -$88.24M+65.1% | ||
| -1.8%+68.4pp | -70.3%+23.8pp | -94.1%+77.8pp | -171.9%+286pp | ||
| -$3.6M+92.3% | -$46.95M+16.2% | -$56.04M+39.1% | -$91.96M+64.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Theravance Biopharma's revenue?
- Theravance Biopharma (TBPH) generated $109.8M in revenue over the trailing twelve months, up 68.2% year over year.
- Is Theravance Biopharma profitable?
- Theravance Biopharma reported $114.5M in net income over the trailing twelve months, a 104.3% net margin.
- What are Theravance Biopharma's profit margins?
- Gross margin is 60.8% and operating margin is 1.2%, with a 104.3% net margin.
- What is Theravance Biopharma's earnings per share?
- Theravance Biopharma's diluted EPS over the trailing twelve months is $2.20.
- Where does Theravance Biopharma's income statement data come from?
- Every line is extracted from Theravance Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
